Evidence map›Paper›PMID 32376560›Full record

ArticleNan fang yi ke da xue xue bao = Journal of Southern Medical University2020

[Expression, purification and functional assessment of asprosin inclusion body].

Xuejing Wei, Qingqing Ao, Ling Meng, Yilu Xu, Cailing Lu, Shen Tang, Xinhang Wang, Xiyi Li

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 59% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Xuejing WeiSchool of Public Health, Guangxi Medical University, Nanning 530021, China.
Qingqing AoSchool of Public Health, Guangxi Medical University, Nanning 530021, China.
Ling MengSchool of Preclinical Medicine, Guangxi Medical University, Nanning 530021, China.
Yilu XuSchool of Public Health, Guangxi Medical University, Nanning 530021, China.
Cailing LuSchool of Public Health, Guangxi Medical University, Nanning 530021, China.
Shen TangSchool of Preclinical Medicine, Guangxi Medical University, Nanning 530021, China.
Xinhang WangSchool of Preclinical Medicine, Guangxi Medical University, Nanning 530021, China.
Xiyi LiSchool of Public Health, Guangxi Medical University, Nanning 530021, China.
Guangxi Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThe obtain purified recombinant asprosin and test its functions.

methodsThe recombinant plasmid of pET-22b-asprosin was constructed and transformed into competent

resultsAt the absorbance at 600 nm of 0.8, induction of the recombinant host bacteria with 1 mmol/L IPTG at 37 ℃ for 4 h optimally induced the expression of asprosin inclusion body. After purification and endotoxin removal, the purity of the recombinant asprosin exceeded 95% with the content of endotoxin below 1 EU/mg. In C57 mice, intraperitoneal injection with recombinant asprosin significantly increased blood glucose level, which reached the peak level at 60 min following the injection (

conclusionsWe successfully obtained recombinant asprosin using a prokaryotic expression system. The recombinant asprosin can decrease glycogen content in MIHA cells and increase blood glucose level in mice.

Indexed as

Inclusion BodiesAdipokinesAnimalsBlood GlucoseCell LineEscherichia coliFibrillin-1GlycogenHumansMiceMice, Inbred C57BLMicrofilament ProteinsPeptide FragmentsPeptide HormonesPlasmidsRecombinant ProteinsAdipokinesBlood GlucoseFBN1 protein, humanFibrillin-1GlycogenMicrofilament ProteinsPeptide FragmentsPeptide HormonesRecombinant Proteinsasprosinblood glucoseglycogeninclusion bodyprokaryotic expression system

Identifiers

PMID32376560
PMCPMC7040760
OpenAlexW3026728950

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.